ME02343B - Derivati alfa-aminoamida korisni u liječenju kognitivnih poremećaja - Google Patents
Derivati alfa-aminoamida korisni u liječenju kognitivnih poremećajaInfo
- Publication number
- ME02343B ME02343B MEP-2016-23A MEP2316A ME02343B ME 02343 B ME02343 B ME 02343B ME P2316 A MEP2316 A ME P2316A ME 02343 B ME02343 B ME 02343B
- Authority
- ME
- Montenegro
- Prior art keywords
- alpha
- treatment
- cognitive disorders
- derivatives useful
- aminoamide derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/402—1-aryl substituted, e.g. piretanide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06012352A EP1870097A1 (en) | 2006-06-15 | 2006-06-15 | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders |
| PCT/EP2007/005197 WO2007144153A2 (en) | 2006-06-15 | 2007-06-13 | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders |
| EP07725989.3A EP2029130B1 (en) | 2006-06-15 | 2007-06-13 | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02343B true ME02343B (me) | 2016-06-20 |
Family
ID=37103353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2016-23A ME02343B (me) | 2006-06-15 | 2007-06-13 | Derivati alfa-aminoamida korisni u liječenju kognitivnih poremećaja |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US8741957B2 (me) |
| EP (4) | EP1870097A1 (me) |
| JP (2) | JP2009539908A (me) |
| KR (1) | KR20090018817A (me) |
| CN (2) | CN101466366A (me) |
| AR (1) | AR061505A1 (me) |
| AU (1) | AU2007260239B2 (me) |
| BR (1) | BRPI0712994A2 (me) |
| CA (1) | CA2655243C (me) |
| CY (1) | CY1116699T1 (me) |
| DK (1) | DK2029130T3 (me) |
| EA (1) | EA018006B1 (me) |
| ES (1) | ES2549113T3 (me) |
| HK (1) | HK1170429A1 (me) |
| HR (1) | HRP20151026T1 (me) |
| HU (1) | HUE026484T2 (me) |
| IL (1) | IL195906A (me) |
| ME (1) | ME02343B (me) |
| MX (1) | MX2008016017A (me) |
| NZ (1) | NZ573565A (me) |
| PL (1) | PL2029130T3 (me) |
| PT (1) | PT2029130E (me) |
| RS (1) | RS54324B1 (me) |
| SI (1) | SI2029130T1 (me) |
| TW (1) | TWI494293B (me) |
| WO (1) | WO2007144153A2 (me) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1658062T3 (da) * | 2003-08-25 | 2010-05-31 | Newron Pharm Spa | Alfa-aminoamid-derivater anvendelige som anti-inflammatoriske midler |
| EP1870097A1 (en) * | 2006-06-15 | 2007-12-26 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders |
| BRPI0712936B8 (pt) | 2006-06-19 | 2021-05-25 | Newron Pharm Spa | processo para a produção de 2-[4-(3- e 2-fluorbenziloxi)benzila-mino]propanamidas |
| CN101687773B (zh) | 2007-06-15 | 2014-07-30 | 纽朗制药有限公司 | 取代的2-[2-(苯基)乙氨基]烷酰胺衍生物及其作为钠和/或钙通道调节剂的应用 |
| EA019529B1 (ru) * | 2007-12-19 | 2014-04-30 | Ньюрон Фармасьютикалс С.П.А. | Альфа-аминоамидные производные, применяемые в лечении психиатрических расстройств |
| EP2314569A1 (en) | 2009-10-22 | 2011-04-27 | Merck Patent GmbH | Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof |
| WO2011055383A2 (en) | 2009-11-06 | 2011-05-12 | Lyka Labs Limited | Intranasal delivery to improve the performance of children suffering from dyslexia |
| US8255838B2 (en) * | 2010-01-15 | 2012-08-28 | Synopsys, Inc. | Etch-aware OPC model calibration by using an etch bias filter |
| WO2011098456A1 (en) * | 2010-02-09 | 2011-08-18 | Merck Serono S.A. | Safinamide in the treatment of dyskinesia |
| KR101851118B1 (ko) | 2010-04-27 | 2018-04-23 | 뉴론 파마슈티칼즈 에스. 피. 에이. | 랄핀아미드 메탄설포네이트 염들 또는 이들의 ｒ―에난티오머들의 제조 방법 |
| WO2013139861A1 (en) | 2012-03-20 | 2013-09-26 | Luc Montagnier | Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders |
| ES2426539B1 (es) | 2012-04-18 | 2014-09-09 | Dr Healthcare España, S. L. | Uso de la diaminooxidasa para el tratamiento o la prevención del trastorno por deficit de atencion con hiperactividad (adhd) |
| KR101420218B1 (ko) * | 2012-06-13 | 2014-07-17 | 이우일 | 생리적안정도 측정 시스템 및 그 방법 |
| CN104546747A (zh) * | 2014-11-20 | 2015-04-29 | 美吉斯制药（厦门）有限公司 | 一种含有甲磺酸沙芬酰胺的药物组合物及其制备方法 |
| CN105456214A (zh) * | 2015-12-30 | 2016-04-06 | 蔡惠文 | 甲磺酸沙芬酰胺片 |
| KR101970099B1 (ko) * | 2018-02-07 | 2019-04-17 | 한국과학기술연구원 | 척수 손상의 예방 및 치료용 조성물 |
| KR102005019B1 (ko) * | 2018-04-04 | 2019-07-31 | 한국과학기술연구원 | 뇌졸중의 예방 및 치료용 조성물 |
| AU2019271189A1 (en) * | 2018-05-15 | 2021-01-07 | Lloyd Hung Loi TRAN | Therapeutic agent composition and method of use, for treatment of mild cognitive impairment, depression, and psychological disorders |
| WO2020234275A1 (en) * | 2019-05-21 | 2020-11-26 | H. Lundbeck A/S | New catecholamine prodrugs for use in the treatment of parkinson's diseases |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1140748A (en) | 1966-06-23 | 1969-01-22 | Ici Ltd | New carboxylic acid derivatives |
| US3795739A (en) | 1972-02-14 | 1974-03-05 | Hoffmann La Roche | Treatment of parkinson disease |
| US4049663A (en) | 1972-06-06 | 1977-09-20 | Allen & Hanburys Limited | Ethylene diamine derivatives |
| FR2480747A1 (fr) | 1980-04-17 | 1981-10-23 | Roques Bernard | Derives d'acides amines et leur application therapeutique |
| EP0331620B1 (de) | 1988-03-01 | 1993-08-11 | Birkmayer, Walther, Prof. Dr. | Mittel zur Behandlung des Parkinson-Syndroms |
| IL94466A (en) | 1989-05-25 | 1995-01-24 | Erba Carlo Spa | Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation |
| US5221536A (en) | 1990-05-07 | 1993-06-22 | Alza Corporation | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement |
| ATE147978T1 (de) * | 1992-05-27 | 1997-02-15 | Merrell Pharma Inc | Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit |
| GB9306886D0 (en) * | 1993-04-01 | 1993-05-26 | Erba Carlo Spa | Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation |
| CA2219911C (en) | 1995-05-26 | 2004-07-27 | Pfizer Inc. | Combinations for the treatment of parkinsonism containing selective nmda antagonists |
| GB9515411D0 (en) | 1995-07-27 | 1995-09-27 | Pharmacia Spa | N-(4-substituted-benzyl)-2-aminolactam derivatives |
| GB9515412D0 (en) * | 1995-07-27 | 1995-09-27 | Pharmacia Spa | 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives |
| US6479484B1 (en) * | 1997-11-21 | 2002-11-12 | Euro-Celtique S.A. | Substituted 2-aminoacetamides and the use thereof |
| GB9727523D0 (en) | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Alpha-aminoamide derivatives useful as analgesic agents |
| GB9727521D0 (en) | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Substituted 2-benzylamino-2-phenyl-acetamide compounds |
| AU761457B2 (en) | 1998-01-12 | 2003-06-05 | Deborah Wenzel | An additive composition also used as a fuel composition comprising water soluble alcohols |
| FI109453B (fi) | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| US20020019421A1 (en) | 2000-07-05 | 2002-02-14 | Roni Biberman | Compositions and therapy for substance addiction |
| AR044007A1 (es) * | 2003-04-11 | 2005-08-24 | Newron Pharmaceuticals Inc | Metodos para el tratamiento de la enfermedad de parkinson |
| US20050203130A1 (en) * | 2003-12-02 | 2005-09-15 | Erik Buntinx | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| EP1588704A1 (en) | 2004-04-22 | 2005-10-26 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders |
| GB0419199D0 (en) * | 2004-08-27 | 2004-09-29 | Curidium Ltd | Methods of diagnosis |
| EP1870097A1 (en) * | 2006-06-15 | 2007-12-26 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders |
-
2006
- 2006-06-15 EP EP06012352A patent/EP1870097A1/en not_active Withdrawn
-
2007
- 2007-06-13 PT PT77259893T patent/PT2029130E/pt unknown
- 2007-06-13 EP EP11159829A patent/EP2343064A1/en not_active Withdrawn
- 2007-06-13 HU HUE07725989A patent/HUE026484T2/en unknown
- 2007-06-13 EP EP07725989.3A patent/EP2029130B1/en active Active
- 2007-06-13 BR BRPI0712994-7A patent/BRPI0712994A2/pt not_active Application Discontinuation
- 2007-06-13 AU AU2007260239A patent/AU2007260239B2/en active Active
- 2007-06-13 ME MEP-2016-23A patent/ME02343B/me unknown
- 2007-06-13 CN CNA2007800218974A patent/CN101466366A/zh active Pending
- 2007-06-13 PL PL07725989T patent/PL2029130T3/pl unknown
- 2007-06-13 ES ES07725989.3T patent/ES2549113T3/es active Active
- 2007-06-13 CN CN201110301426.7A patent/CN102512406B/zh active Active
- 2007-06-13 JP JP2009514697A patent/JP2009539908A/ja active Pending
- 2007-06-13 KR KR1020087030389A patent/KR20090018817A/ko active Search and Examination
- 2007-06-13 US US12/304,455 patent/US8741957B2/en active Active
- 2007-06-13 DK DK07725989.3T patent/DK2029130T3/en active
- 2007-06-13 SI SI200731694T patent/SI2029130T1/sl unknown
- 2007-06-13 WO PCT/EP2007/005197 patent/WO2007144153A2/en active Application Filing
- 2007-06-13 MX MX2008016017A patent/MX2008016017A/es active IP Right Grant
- 2007-06-13 RS RS20150671A patent/RS54324B1/en unknown
- 2007-06-13 CA CA2655243A patent/CA2655243C/en active Active
- 2007-06-13 EA EA200802306A patent/EA018006B1/ru unknown
- 2007-06-13 NZ NZ573565A patent/NZ573565A/xx unknown
- 2007-06-13 EP EP15179988.9A patent/EP2977046A1/en not_active Withdrawn
- 2007-06-14 TW TW096121477A patent/TWI494293B/zh active
- 2007-06-15 AR ARP070102668A patent/AR061505A1/es unknown
-
2008
- 2008-12-11 IL IL195906A patent/IL195906A/en active IP Right Grant
-
2012
- 2012-11-08 HK HK12111289.3A patent/HK1170429A1/xx unknown
-
2013
- 2013-04-10 JP JP2013082067A patent/JP6119068B2/ja active Active
-
2015
- 2015-09-22 CY CY20151100827T patent/CY1116699T1/el unknown
- 2015-09-29 HR HRP20151026TT patent/HRP20151026T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL195906A0 (en) | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders | |
| IL208607A0 (en) | Improved nanobodiestm for the treatment of aggregation-mediated disorders | |
| HK1126212A1 (en) | Heterocyclic compounds and uses thereof in the treatment of sexual disorders | |
| EP1853295A4 (en) | METHOD AND COMPOSITIONS FOR TREATING GASTROINTESTINAL DISEASES | |
| EP1940441A4 (en) | COMPOSITIONS AND METHODS FOR TREATING GASTROINTESTINAL DISORDERS | |
| EP1893216A4 (en) | METHOD AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES | |
| GB201001047D0 (en) | Methods and compositions for the treatment of neurological disorders | |
| IL193936A0 (en) | Compositions and methods for the treatment of immunoinflammatory disorders | |
| EP1996218A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | |
| HK1247943A1 (zh) | 發育相關疾病的治療 | |
| IL191537A0 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
| IL205578A0 (en) | Aldh-2 inhibitors in the treatment of psychiatric disorders | |
| ZA200806455B (en) | Use of 2-imidazoles for the treatment of CNS disorders | |
| GB0611240D0 (en) | The treatment of increased sebum production | |
| HK1146221A1 (en) | Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders | |
| HK1139855A1 (en) | Specific 3-heteroaryl-3-hydroxy-2-amino-propionic acid amide derivative for use in the treatment of certain cognitive disorders | |
| ZA201108106B (en) | Use of phthalimide derivatives in the treatment of diseases | |
| HK1134032A1 (en) | New combination for use in the treatment of inflammatory disorders | |
| IL192933A0 (en) | Benzoisoindole derivatives for the treatment of pain | |
| IL192877A0 (en) | Use of 2-imidazoles for the treatment of cns disorders | |
| IL209417A0 (en) | 1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders | |
| GB0710277D0 (en) | Use of antivirals in the treatment of medical disorders | |
| PL1982178T3 (pl) | Sposoby leczenia zaburzeń afektywnych | |
| HK1145282A1 (en) | Treatment of sleep disorders | |
| GB0602857D0 (en) | The treatment of sialorrhoea |